NYSE:CPHI China Pharma (CPHI) Stock Forecast, Price & News $0.14 -0.01 (-6.87%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$0.13▼$0.1550-Day Range$0.14▼$0.3652-Week Range$0.11▼$2.46Volume642,705 shsAverage Volume555,663 shsMarket Capitalization$1.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media About China Pharma (NYSE:CPHI) StockChina Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Read More CPHI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPHI Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comChina Pharma (NYSE:CPHI) Research Coverage Started at StockNews.comSeptember 16, 2023 | investing.comChina NT Pharma Group Co Ltd (1011)September 21, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 27, 2023 | msn.comWeek In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's NeucaAugust 24, 2023 | finance.yahoo.comIs China Pharma Holding (CPHI) A Hidden Gem or A Value Trap?August 23, 2023 | msn.comSignal: Chinese economic slump hurts pharma firms invested in the regionAugust 9, 2023 | msn.comGov’t scientists got $325M in royalties from China, Russia, pharma firmsAugust 9, 2023 | markets.businessinsider.comChina Pharma: Candesartan Tablets Passes Generic-drug-consistency-evaluationSeptember 21, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 9, 2023 | finance.yahoo.comChina Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic DrugsJuly 27, 2023 | msn.comPharmaniaga teams up with China's CSPC to boost biopharmaceutical developmentJuly 5, 2023 | reuters.comChina's commerce minister met with foreign pharmaceuticals firms on Wednesday - Commerce MinistryJune 3, 2023 | msn.comFDA to allow imports of cancer drug from China amid ongoing shortageMay 28, 2023 | reuters.comChina regulator fines two pharma firms for monopoly behaviourMay 5, 2023 | finance.yahoo.comViva Biotech's Recent Conferences & Events ReviewApril 28, 2023 | marketwatch.comOx Bezoars (Cow Bezoars) Market Research Analysis 2023-2031April 20, 2023 | markets.businessinsider.comAurisco Expands Oligonucleotide Capacity and Launches New WebsiteFebruary 27, 2023 | finanznachrichten.deChina Pharma Holdings, Inc.: China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock SplitFebruary 25, 2023 | marketwatch.comOx Bezoars (Cow Bezoars) Market Intelligence Report [2023-2028] | Get Ahead of Your Competitors with Our New ReportFebruary 24, 2023 | msn.comChina Pharma launches 1-for-10 reverse stock splitFebruary 24, 2023 | finance.yahoo.comChina Pharma Holdings Inc. Announces 1-for-10 Reverse Stock SplitJanuary 25, 2023 | dailymail.co.ukAntifa terror suspect daughter of Pharma China giant and British Foreign Office consultantDecember 28, 2022 | markets.businessinsider.comChina Pharma Launches N95 Mask - Quick FactsDecember 28, 2022 | finance.yahoo.comChina Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective MaskDecember 15, 2022 | finance.yahoo.comChina Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19December 5, 2022 | marketwatch.comChina Pharma Shares More Than Double After Acquisition of Dry Eye Disease Device ProjectDecember 5, 2022 | finance.yahoo.comChina Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device ProjectSee More Headlines Receive CPHI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CPHI Company Calendar Last Earnings8/14/2023Today9/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:CPHI CUSIPN/A CIK1106644 Webwww.chinapharmaholdings.com Phone8689866811730Fax86-898-6681-9024Employees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,970,000.00 Net Margins-39.33% Pretax Margin-39.33% Return on Equity-77.41% Return on Assets-18.64% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.15 Sales & Book Value Annual Sales$8.10 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book0.24Miscellaneous Outstanding Shares11,430,000Free Float5,854,000Market Cap$1.55 million OptionableNot Optionable Beta0.53 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Zhilin Li (Age 70)Pres, CEO, Chairman & Interim CFO Ms. Huang Na C.F.A.BOD Sec. & IR Mang.Key CompetitorsAyala PharmaceuticalsNASDAQ:ADXSHistogenNASDAQ:HSTOChina SXT PharmaceuticalsNASDAQ:SXTCAltamira TherapeuticsNASDAQ:CYTOScopus BioPharmaNASDAQ:SCPSView All Competitors CPHI Stock - Frequently Asked Questions How have CPHI shares performed in 2023? China Pharma's stock was trading at $0.63 at the start of the year. Since then, CPHI stock has decreased by 78.5% and is now trading at $0.1355. View the best growth stocks for 2023 here. How were China Pharma's earnings last quarter? China Pharma Holdings, Inc. (NYSE:CPHI) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.06) EPS for the quarter. The business had revenue of $1.10 million for the quarter. China Pharma had a negative trailing twelve-month return on equity of 77.41% and a negative net margin of 39.33%. When did China Pharma's stock split? Shares of China Pharma reverse split on Monday, March 6th 2023. The 1-10 reverse split was announced on Monday, March 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of China Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other China Pharma investors own include iShares Silver Trust (SLV), Check-Cap (CHEK), ContraFect (CFRX), Clear Channel Outdoor (CCO), Boxlight (BOXL), Bionano Genomics (BNGO), Athersys (ATHX), Assertio (ASRT), AMC Entertainment (AMC). What is China Pharma's stock symbol? China Pharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CPHI." How do I buy shares of China Pharma? Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is China Pharma's stock price today? One share of CPHI stock can currently be purchased for approximately $0.14. How much money does China Pharma make? China Pharma (NYSE:CPHI) has a market capitalization of $1.55 million and generates $8.10 million in revenue each year. How many employees does China Pharma have? The company employs 234 workers across the globe. How can I contact China Pharma? China Pharma's mailing address is Second Floor No. 17 Jinpan Road, Haikou F4, 570216. The official website for the company is www.chinapharmaholdings.com. The company can be reached via phone at 8689866811730, via email at hps@chinapharmaholdings.com, or via fax at 86-898-6681-9024. This page (NYSE:CPHI) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.